Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Discover how innovative physical therapy, smart medications, nutrition strategies and mind-body techniques are transforming ...

Don’t fall for the distraction of tariffs. To reduce fentanyl deaths, we need to get opioid users into treatment and reduce ...

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

Study objective There is no consensus on the management of low back pain in the ED and evidence suggests that these patients are likely to receive unwarranted imaging and inappropriate opioid ...

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...